Shots:
BI has entered into an agreement with Synaffix (Lonza’s company) to license the latter’s ADC technology, boosting its oncology pipeline via NBE Therapeutics (BI’s subsidiary)
As per the terms, BI will access Synaffix’s platform for a specified but undisclosed number of targets, with the first target nominated & others to follow within a…
